 |
0 Diseases |  |
137 Trials |
|
137 Trials |  |
5343 News |  |
| «12...7778798081828384858687...9091» |
- || ExPEC vaccine (JNJ-1860) / J&J, GSK
Clinical, Journal: Epidemiology and O-Serotypes of Extraintestinal Pathogenic Escherichia coli Disease in Patients Undergoing Transrectal Ultrasound Prostate Biopsy: A Prospective Multicenter Study. (Pubmed Central) - Oct 23, 2020
This study provides an estimate of microbiologically confirmed invasive ExPEC disease incidence following TRUS-PNB. Information on E. coli O-serotype distribution and associated antibiotic resistance profiles from invasive ExPEC disease cases in the first 30 days following TRUS-PNB may help guiding antibiotic use and inform development of a prophylactic ExPEC vaccine.
- | Gatiflox (gatifloxacin) / Orient Europharma, NN1213 / Novo Nordisk, Besivance (besifloxacin ophthalmic suspension) / Bausch Health
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis (clinicaltrials.gov) - Oct 20, 2020
P3, N=35, Completed, Sponsor: University Hospital, Geneva
Information on E. coli O-serotype distribution and associated antibiotic resistance profiles from invasive ExPEC disease cases in the first 30 days following TRUS-PNB may help guiding antibiotic use and inform development of a prophylactic ExPEC vaccine. Recruiting --> Completed | N=252 --> 35 | Trial completion date: Aug 2021 --> Oct 2020 | Trial primary completion date: Mar 2021 --> Oct 2020
- | levofloxacin / Generic mfg.
Trial completion date, Trial primary completion date, Combination therapy: Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB (clinicaltrials.gov) - Oct 19, 2020
P2, N=111, Active, not recruiting, Sponsor: Boston University
Recruiting --> Completed | N=252 --> 35 | Trial completion date: Aug 2021 --> Oct 2020 | Trial primary completion date: Mar 2021 --> Oct 2020 Trial completion date: Sep 2020 --> Mar 2021 | Trial primary completion date: Sep 2020 --> Mar 2021
- || Actemra IV (tocilizumab) / Roche, JW Pharma, Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Kineret (anakinra) / SOBI
Enrollment change, Trial completion date, Trial primary completion date: Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants (clinicaltrials.gov) - Oct 19, 2020
P=N/A, N=1600, Recruiting, Sponsor: Duke University
Trial completion date: Sep 2020 --> Mar 2021 | Trial primary completion date: Sep 2020 --> Mar 2021 N=500 --> 1600 | Trial completion date: Sep 2020 --> Sep 2021 | Trial primary completion date: Sep 2020 --> Sep 2021
- || levofloxacin / Generic mfg.
Trial completion date, Trial primary completion date: The Pharmacokinetics of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5% (clinicaltrials.gov) - Oct 14, 2020
P1/2, N=128, Recruiting, Sponsor: National University of Malaysia
N=500 --> 1600 | Trial completion date: Sep 2020 --> Sep 2021 | Trial primary completion date: Sep 2020 --> Sep 2021 Trial completion date: Aug 2021 --> May 2022 | Trial primary completion date: Aug 2020 --> Aug 2021
- || levofloxacin / Generic mfg.
Trial completion date, Trial primary completion date: The Clinical Safety of Levofloxacin 1.5% vs Topical Moxifloxacin 0.5% (clinicaltrials.gov) - Oct 14, 2020
P1/2, N=128, Recruiting, Sponsor: National University of Malaysia
Trial completion date: Aug 2021 --> May 2022 | Trial primary completion date: Aug 2020 --> Aug 2021 Trial completion date: Aug 2021 --> May 2022 | Trial primary completion date: Aug 2020 --> Aug 2021
- | Trial completion: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) - Oct 13, 2020
P4, N=1578, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial completion date: Aug 2021 --> May 2022 | Trial primary completion date: Aug 2020 --> Aug 2021 Active, not recruiting --> Completed
- | levofloxacin / Generic mfg., clindamycin phosphate / Generic mfg.
Biomarker, New trial: Initial Management of MRONJ Stages I and II, a Clinical Trial With Detection of Salivary Biomarkers (clinicaltrials.gov) - Oct 12, 2020
P=N/A, N=50, Not yet recruiting, Sponsor: Fundaci
- | oseltamivir / Generic mfg., favipiravir / Generic mfg.
New P3 trial: The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19 (clinicaltrials.gov) - Sep 21, 2020
P3, N=100, Recruiting, Sponsor: Indonesia University
- || levofloxacin / Generic mfg., cefuroxime / Generic mfg.
Trial completion date, Trial primary completion date: Intracameral Levofloxacin (0.5%) vs Intracameral Cefuroxime (clinicaltrials.gov) - Sep 19, 2020
P1/2, N=138, Recruiting, Sponsor: National University of Malaysia
Active, not recruiting --> Completed Trial completion date: Oct 2020 --> Oct 2022 | Trial primary completion date: May 2020 --> Jan 2022
- | relebactam (MK-7655) / Merck (MSD)
Journal, Combination therapy: Activity of aztreonam in combination with avibactam, clavulanate, relebactam, and vaborbactam against multidrug resistant Stenotrophomonas maltophilia. (Pubmed Central) - Sep 18, 2020
Decreased susceptibility may be due to the combination of overexpressed β-lactamases and efflux pumps. Further studies evaluating this combination against S. maltophilia are warranted.
- | levofloxacin / Generic mfg., doxycycline / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: Comparing Efficacy of 14-day Therapy Doxycycline With Bismuth Subsalicylate Versus Levofloxacin With Tinadizole on Treatment Helicobacter Pylori (clinicaltrials.gov) - Sep 15, 2020
P4, N=78, Completed, Sponsor: Damascus Hospital
Further studies evaluating this combination against S. maltophilia are warranted. Recruiting --> Completed | Trial completion date: Apr 2021 --> Sep 2020 | Trial primary completion date: Jan 2021 --> Aug 2020
- | PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Trial completion date, Trial primary completion date, Pneumococcal vaccines: Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents (clinicaltrials.gov) - Sep 2, 2020
P4, N=40, Enrolling by invitation, Sponsor: Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
Recruiting --> Completed | Trial completion date: Apr 2021 --> Sep 2020 | Trial primary completion date: Jan 2021 --> Aug 2020 Trial completion date: Jul 2020 --> Dec 2020 | Trial primary completion date: May 2020 --> Nov 2020
- ||||| New P4 trial: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum (clinicaltrials.gov) - Aug 19, 2020
P4, N=325, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- | levofloxacin / Generic mfg., rifampicin / Generic mfg.
Enrollment closed: TBM-KIDS: Optimizing Treatment to Improve TBM Outcomes in Children (clinicaltrials.gov) - Aug 13, 2020
P1/2, N=120, Active, not recruiting, Sponsor: Johns Hopkins University
Trial completion date: Jul 2020 --> Dec 2020 | Trial primary completion date: May 2020 --> Nov 2020 Recruiting --> Active, not recruiting
- | Invanz (ertapenem) / Merck (MSD)
Enrollment open: Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy (clinicaltrials.gov) - Aug 10, 2020
P4, N=100, Recruiting, Sponsor: Roswell Park Cancer Institute
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date, Head-to-Head: ENVELOPE: Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections. (clinicaltrials.gov) - Aug 10, 2020
P3, N=1492, Recruiting, Sponsor: Vanderbilt University Medical Center
Not yet recruiting --> Recruiting Trial completion date: Aug 2020 --> Aug 2021 | Trial primary completion date: Jul 2020 --> Jul 2021
- | levofloxacin / Generic mfg., clindamycin phosphate / Generic mfg., trimethoprim/sulfamethoxazole / Generic mfg.
New trial: Susceptibility Testing of Biofilm to Guide Treatment of Periprosthetic Joint Infections (clinicaltrials.gov) - Aug 6, 2020
P=N/A, N=40, Not yet recruiting, Sponsor: Vastra Gotaland Region
- | Invanz (ertapenem) / Merck (MSD)
New P4 trial: Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy (clinicaltrials.gov) - Aug 6, 2020
P4, N=100, Not yet recruiting, Sponsor: Roswell Park Cancer Institute
- || clarithromycin / Generic mfg.
Clinical, Journal: Treatment of Helicobacter pylori infection: a clinical practice update. (Pubmed Central) - Jul 24, 2020
Probiotic supplementation should be used with the aim to reduce antibiotic-related adverse events. Recent evidence would support current guideline recommendations for the treatment of Helicobacter pylori infection.
- | Enrollment open, Enrollment change: Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care (clinicaltrials.gov) - Jul 23, 2020
P3, N=400, Recruiting, Sponsor: Wits Health Consortium (Pty) Ltd
Recent evidence would support current guideline recommendations for the treatment of Helicobacter pylori infection. Active, not recruiting --> Recruiting | N=85 --> 400
- | levofloxacin / Generic mfg., amikacin sulfate / Generic mfg.
Enrollment open: TB-TRUST: Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T) (clinicaltrials.gov) - Jul 23, 2020
P=N/A, N=354, Recruiting, Sponsor: Huashan Hospital
Active, not recruiting --> Recruiting | N=85 --> 400 Not yet recruiting --> Recruiting
- | levofloxacin / Generic mfg.
New P4 trial: Effect of Ciprofloxacin Versus Levofloxacin on QTc-interval and Dysglycemia (clinicaltrials.gov) - Jul 1, 2020
P4, N=200, Completed, Sponsor: Beni-Suef University
- || ceftriaxone / Generic mfg.
Clinical, Journal: A case report of fulminant endophthalmitis caused by Streptococcus dysgalactiae in a patient with traumatic corneal laceration. (Pubmed Central) - Jun 23, 2020
Progression of traumatic endophthalmitis associated with S. dysgalactiae can be fulminant. Sufficient warning to patient about enucleation and intensive care is needed in the case of this infection.
- | New P4 trial: Intravenous Triple Therapy in the Treatment of Helicobacter Pylori Infection and Related Complications Caused by Active Peptic Ulcer Disease (clinicaltrials.gov) - Jun 15, 2020
P4, N=60, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
- | levofloxacin / Generic mfg.
New P4 trial, Surgery: Postoperative Safety Outcomes of Intraoperative Intracameral Preservative-Free Moxifloxacin Versus Levofloxacin (clinicaltrials.gov) - May 26, 2020
P4, N=114, Completed, Sponsor: Peregrine Eye and Laser Institute
- | levofloxacin / Generic mfg., tetracycline / Generic mfg.
Enrollment open, Trial primary completion date: Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the Rescue Treatment of Helicobacter Pylori Infection (clinicaltrials.gov) - May 11, 2020
P4, N=400, Recruiting, Sponsor: Shandong University
Sufficient warning to patient about enucleation and intensive care is needed in the case of this infection. Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2019 --> May 2020
- | Trial completion, Trial completion date: Efficacies of Antimicrobial Susceptibility-Guided Versus Empirical Therapy for Rescue Treatment of Helicobacter Pylori Infection (clinicaltrials.gov) - May 11, 2020
P4, N=420, Completed, Sponsor: Shandong University
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2019 --> May 2020 Not yet recruiting --> Completed | Trial completion date: Apr 2020 --> Dec 2019
- | ciprofloxacin oral / Generic mfg.
New trial: Efficacy of Ciprofloxacin Therapy in Avoidance of Sepsis in Patient Undergoing Percutanous Nephrolithotomy (clinicaltrials.gov) - May 4, 2020
P=N/A, N=200, Recruiting, Sponsor: Diaa Eldin Taha Ramadan Mohamed
- ||| New trial: Prospective Randomised Trial of First and Second Line Treatments of RCT of First and Second Line H Pylori Treatments in Slovenia (clinicaltrials.gov) - Apr 23, 2020
P=N/A, N=560, Not yet recruiting, Sponsor: Slovenian Society for Gastroenterology and Hepatology
- | pantoprazole / Generic mfg., levofloxacin / Generic mfg., amoxicillin / Generic mfg.
New trial: Melatonin Supplementation in Postmenopausal Women With H. Pylori-associated Dyspepsia (clinicaltrials.gov) - Apr 16, 2020
P=N/A, N=152, Completed, Sponsor: Medical Universtity of Lodz
- | ceftriaxone / Generic mfg.
Journal: Emerging coexistence of three PMQR genes on a multiple resistance plasmid with a new surrounding genetic structure of qnrS2 in E. coli in China. (Pubmed Central) - Apr 16, 2020
We revealed the coexistence of three PMQR genes on a multiple resistance plasmid and a new surrounding genetic structure of qnrS2 flanked by IS26 elements. IS26 plays an important role in horizontal spread of quinolone resistance.
- | Trial completion date: REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - Apr 15, 2020
P4, N=7100, Recruiting, Sponsor: MJM Bonten
IS26 plays an important role in horizontal spread of quinolone resistance. Trial completion date: Jun 2022 --> Dec 2023
- | levofloxacin / Generic mfg., doxycycline / Generic mfg.
New P4 trial: Comparing Efficacy of 14-day Therapy Doxycycline With Bismuth Subsalicylate Versus Levofloxacin With Tinadizole on Treatment Helicobacter Pylori (clinicaltrials.gov) - Apr 15, 2020
P4, N=100, Recruiting, Sponsor: Damascus Hospital
- | AzaSite (1% azithromycin ophthalmic solution) / Sun Pharma, Akorn, Nicox
Trial completion date, Trial primary completion date: Healthy Patients & Effect of Antibiotics (clinicaltrials.gov) - Apr 6, 2020
P=N/A, N=20, Active, not recruiting, Sponsor: Washington University School of Medicine
Trial completion date: Jun 2022 --> Dec 2023 Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020
- | levofloxacin / Generic mfg.
New P4 trial: Susceptibility Testing Guided Versus Empirical Therapy for Refractory H. Pylori Infection (clinicaltrials.gov) - Apr 2, 2020
P4, N=360, Not yet recruiting, Sponsor: National Taiwan University Hospital
- | Sivextro (tedizolid) / Merck (MSD), Nabriva Therap
Trial completion date, Trial primary completion date: TEDIZOAM: Tedizolid Prolonged Treatment for Prosthetic Joint Infections (clinicaltrials.gov) - Apr 2, 2020
P=N/A, N=35, Active, not recruiting, Sponsor: Tourcoing Hospital
Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020 Trial completion date: Jan 2020 --> Aug 2021 | Trial primary completion date: Dec 2019 --> Dec 2020
- | Enrollment closed, Enrollment change: Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care (clinicaltrials.gov) - Mar 31, 2020
P3, N=85, Active, not recruiting, Sponsor: Wits Health Consortium (Pty) Ltd
Trial completion date: Jan 2020 --> Aug 2021 | Trial primary completion date: Dec 2019 --> Dec 2020 Recruiting --> Active, not recruiting | N=400 --> 85
- | levofloxacin / Generic mfg.
Trial completion date, Trial primary completion date, Combination therapy: Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB (clinicaltrials.gov) - Mar 23, 2020
P2, N=111, Active, not recruiting, Sponsor: Boston University
Recruiting --> Active, not recruiting | N=400 --> 85 Trial completion date: Mar 2020 --> Sep 2020 | Trial primary completion date: Mar 2020 --> Sep 2020
- | NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: Personalized Treatment for Refractory H Pylori Infection (clinicaltrials.gov) - Mar 16, 2020
P=N/A, N=150, Recruiting, Sponsor: Kaohsiung Veterans General Hospital.
Trial completion date: Mar 2020 --> Sep 2020 | Trial primary completion date: Mar 2020 --> Sep 2020 Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020
- | levofloxacin / Generic mfg., tetracycline / Generic mfg.
Trial completion date, Trial primary completion date: Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies (clinicaltrials.gov) - Mar 16, 2020
P3, N=918, Recruiting, Sponsor: Kaohsiung Veterans General Hospital.
Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020 Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Jul 2020 --> Jul 2021
- | Trial completion date, Trial primary completion date: Efficacies of Two Bismuth Quadruple Therapies in the Second-line Treatment of H Pylori Infection (clinicaltrials.gov) - Mar 16, 2020
P=N/A, N=184, Recruiting, Sponsor: Ping-I (William) Hsu, M.D.
Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Jul 2020 --> Jul 2021 Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Jul 2020 --> Jul 2021
- | NN1213 / Novo Nordisk
Trial completion date: Oral Versus Topical Antibiotics for Chronic Rhinosinusitis Exacerbations (clinicaltrials.gov) - Mar 11, 2020
P3, N=33, Active, not recruiting, Sponsor: University of Rochester
Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Jul 2020 --> Jul 2021 Trial completion date: Dec 2019 --> Dec 2020
- | levofloxacin / Generic mfg.
Trial completion, Enrollment change: Short Compared With Standard Duration of Antibiotic Treatment for AECOPD (clinicaltrials.gov) - Feb 24, 2020
P2, N=150, Completed, Sponsor: University of Monastir
Trial completion date: Dec 2019 --> Dec 2020 Recruiting --> Completed | N=520 --> 150
- | PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Trial completion date, Trial primary completion date, Pneumococcal vaccines: Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents (clinicaltrials.gov) - Feb 23, 2020
P4, N=40, Enrolling by invitation, Sponsor: Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
Recruiting --> Completed | N=520 --> 150 Trial completion date: Dec 2019 --> Jul 2020 | Trial primary completion date: Dec 2019 --> May 2020
- | levofloxacin / Generic mfg.
Trial completion date, Trial primary completion date: Short Antibiotic Treatment Versus Duration Guided by Markers of Inflammation in the Treatment of AECOPD (clinicaltrials.gov) - Feb 23, 2020
P2, N=520, Recruiting, Sponsor: University of Monastir
Trial completion date: Dec 2019 --> Jul 2020 | Trial primary completion date: Dec 2019 --> May 2020 Trial completion date: Dec 2018 --> Dec 2022 | Trial primary completion date: Dec 2018 --> Dec 2022
- | Invanz (ertapenem) / Merck (MSD), Timcynis (ticarcillin and clavulanic acid) / Emcure, NN1213 / Novo Nordisk
Enrollment closed: The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial (clinicaltrials.gov) - Feb 20, 2020
P=N/A, N=1552, Active, not recruiting, Sponsor: University of Washington
Trial completion date: Dec 2018 --> Dec 2022 | Trial primary completion date: Dec 2018 --> Dec 2022 Recruiting --> Active, not recruiting
- | levofloxacin / Generic mfg.
Journal: Ureaplasma parvum causes hyperammonemia presenting as refractory status epilepticus after kidney transplant. (Pubmed Central) - Feb 19, 2020
Ureaplasma infection must be suspected in cases of neurological symptoms associated with hyperammonemia without liver failure, following an organ transplant. Only urgent treatment could improve the prognosis and prevent severe neurological damage or death.
- | levofloxacin / Generic mfg.
New P3 trial: Early De-escalation of Empirical Antibiotics Treatment for Neutropenic Fever (clinicaltrials.gov) - Feb 16, 2020
P3, N=200, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
- | Trial completion date, Trial primary completion date: BISER: Bacteriology and Inflammation in Bronchiectasis (clinicaltrials.gov) - Feb 11, 2020
P=N/A, N=80, Recruiting, Sponsor: Guangzhou Institute of Respiratory Disease
Only urgent treatment could improve the prognosis and prevent severe neurological damage or death. Trial completion date: Dec 2020 --> Dec 2023 | Trial primary completion date: Dec 2020 --> Dec 2023